Nerandomilast
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Nerandomilast for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Clinical Efficacy, Safety, and Place in Therapy.
Journal: The Annals of pharmacotherapy
Published: May 18, 2026
Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies.
Journal: Journal of clinical medicine
Published: March 31, 2026
2025 annual review of basic and translational research advances in pulmonary fibrosis: a narrative review.
Journal: Journal of thoracic disease
Published: March 21, 2026
Management of Progressive Pulmonary Fibroses - 2025 Update
Journal: Deutsche medizinische Wochenschrift (1946)
Published: March 09, 2026
Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies.
Journal: Journal of clinical medicine
Published: February 17, 2026
Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials.
Journal: BMC pulmonary medicine
Published: February 12, 2026
Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases
Journal: Zeitschrift fur Rheumatologie
Published: January 26, 2026
Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway.
Journal: RMD open
Published: January 04, 2026
Last Updated: 06/30/2026